GenFleet Therapeutics (Shanghai) Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
GenFleet Therapeutics (Shanghai) Inc. - overview
Established
2017
Location
Shanghai, -, China
Primary Industry
Pharmaceuticals
About
Founded in 2017 and based in Shanghai, China, GenFleet Therapeutics specializes in drug development focusing on oncology and immunology. In September 2025, GenFleet Therapeutics (Shanghai) Inc. raised HKD 1. 82 billion in an IPO, selling 89.
24 million shares at HKD 20. 39 per share at Hong Kong Stock Exchange under the ticker symbol "2595". GenFleet Therapeutics (Shanghai) Inc. provides oncology and immunology.
The company's pipeline includes small and large molecule therapeutics targeting unvalidated clinical indications. The company product, Daberit® (Furazepirase), is the first KRAS G12C inhibitor approved in China and the third globally. The company generates revenue by researching and developing innovative therapeutic products, focusing on solid tumors, hematological malignancies, and autoimmune diseases and other related products.
Current Investors
Shijiazhuang Pharma, Shanghai Jianyi Private Equity Fund Management, Ally Bridge Group
Primary Industry
Pharmaceuticals
Sub Industries
Molecular Science, Genetics & Gene Therapy, Epidemiology, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.genfleet.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.